PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$9.1 0.7  8.1%

Last Trade - 3:55pm

Small Cap
Market Cap £180.5m
Enterprise Value £127.9m
Revenue £n/a
Position in Universe 4651st / 7335

PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference

Tue 7th September, 2021 1:30pm
For best results when printing this announcement, please click on link below:

FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies based on the Company’s proprietary Versamune(®)
T-cell activating technology, announced today that its management will present
at the HC Wainwright 23rd Annual Global Investment Conference. 

The presentation will provide an update on the three ongoing PDS0101 Phase 2
clinical trials. The talk will also provide updates on progression of two
other investigational pipeline products PDS0102 (Versamune(®)-TARP) and
PDS0103 (Versamune(®)-MUC1) into human clinical trials. The conference is
taking place virtually from September 13 - 15, 2021. 

HC Wainwright 23rd Annual Global Investment Conference:
Investors can register for the conference HERE.

The presentation will be available on demand beginning at 7:00 am EDT on
Monday, September 13, 2021 within the Investor section of the company’s
website, https://pdsbiotech.com/.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing
pipeline of cancer immunotherapies based on the Company’s proprietary
Versamune(®) T-cell activating technology platform. Our Versamune(®)-based
products have demonstrated the potential to overcome the limitations of
current immunotherapy by inducing in vivo, large quantities of high-quality,
highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer
T-cells. PDS Biotech has developed multiple therapies, based on combinations
of Versamune(®) and disease-specific antigens, designed to train the immune
system to better recognize diseased cells and effectively attack and destroy
them. The company’s pipeline products address various cancers including
breast, colon, lung, prostate and ovarian cancers.  To learn more, please
visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101
PDS Biotech’s lead candidate, PDS0101, combines the utility of the
Versamune(®) platform with targeted antigens in HPV-expressing cancers. In
partnership with Merck & Co., PDS Biotech is evaluating a combination of
PDS0101 and KEYTRUDA(®) in a Phase 2 study in first-line treatment of
recurrent or metastatic head and neck cancer. PDS Biotech is also conducting
two additional Phase 2 studies in advanced HPV-associated cancers and advanced
localized cervical cancer with the National Cancer Institute (NCI) and The
University of Texas MD Anderson Cancer Center, respectively.

Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838 
Email: rich@cg.capital


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.